Imatib 400mg Tablet

The human body reacts differently to Imatib 400 mg tablet. Response or undesired symptoms vary from individual to individual. Usually, they disappear with time as the body adjusts to the medicine; these side effects don't need special medical attention. Whereas if the symptoms don't disappear with time or you have severe side effects, then consult your doctor immediately.
Some of the common side effects of Imatib 400 mg tablet are mentioned below:

• Difficulty in breathing.
  
• Indigestion
  
• Constipation
  
• Weight loss
  
• Acidic stomach
  
• Change in taste
  
• Dry mouth
  
• Joint pain
  
• Irregular heartbeat.
  
• Unusual bleeding.
  
• Presence of blood in coughing.
  
• Abdominal pain.
  
• Swelling around the eyes.

• Imatib 400 mg Tablet is an anti-cancer medication that inhibits the proliferation of BCR-ABL tyrosine kinase, a protein enzyme.
• This enzyme helps cancer cells multiply and is responsible for the abnormal proliferation of cancer cells.
• Imatib 400 mg Tablet also induces apoptosis (programmed cell death) in BCR-ABL positive cells (cancer cells).
  

1. Alwan AF, Matti BF, Naji AS, Muhammed AH, Abdulsahib MA. (2024). Prospective single-center study of chronic myeloid leukemia in chronic phase: switching from branded imatinib to a copy drug and back. Leuk Lymphoma. 55(12):2830 - https://pubmed.ncbi.nlm.nih.gov/24628295/
   
2. Morishima Y, Ogura M, Nishimura M, Yazaki F, Bessho M, Mizoguchi H, Chiba S, Hirai H, Tauchi T, Urabe A, Takahashi M, Ohnishi K, Yokozawa T, Emi N, Hirano M, Shimazaki C, Nakao S, Kawai Y, Fujimoto M, Taguchi H, Jinnai I, Ohno R. (2023).  Efficacy and safety of imatinib mesylate for patients in the first chronic phase of chronic myeloid leukemia: results of a Japanese phase II clinical study. Int J Hematol. 80(3):261-6 - https://link.springer.com/article/10.1532/IJH97.04074
   
3. Hołowiecki J, Konopka L, Bober G, Giebel S, Ceglarek B, Kos K, Stella-Hołowiecka B, Kruzel T, Kopera M, Bartkowska-Chrobok A, Pszenna E, Sikorska A, Pieńikowska-Grela B. (2023).Ocena skuteczności i bezpieczeńistwa stosowania imatinibu mesylate u pacjentów z faza przewlekła przewlekłej białaczki szpikowej po niepowodzeniu leczenia interferonem 4 lata obserwacji [A study to determine the safety and efficacy of imatinib mesylate in patients with chronic phase of chronic myeloid leukemia after interferon therapy failure. Four year follow-up]. Pol Arch Med Wewn. 115(6):535-44.
   
4. Mathews V. (2025). Generic imatinib: the real deal or just a deal? Leuk Lymphoma. 2014 55(12):2678-80 - https://www.cmladvocates.net/wp-content/uploads/2022/06/2014-Vikram-Mathews-Generic-imatinib-a-real-deal-or-just-a-deal-2014.pdf
   
5. Alwan AF. (2025). Rebuttal and response to: "The efficacy and tolerability issue of generics of imatinib in the treatment of chronic myeloid leukemia: do generics really jeopardize patient safety?" by Ahmet Emre Eskazan, Muhlis Cem Ar, and Teoman Soysal. Leuk Lymphoma. 56(4):1181.
   
6. Murai K, Akagi T, Shimosegawa K, Sugawara T, Ishizawa K, Ito S, Murai K, Motegi M, Yokoyama H, Noji H, Tajima K, Kimura J, Chou T, Ogawa K, Harigae H, Kubo K, Oba K, Sakamoto J, Ishida Y. (2025). A prospective analysis of clinical efficacy and safety in chronic myeloid leukemia-chronic phase patients with imatinib resistance or intolerance as evaluated using European LeukemiaNet 2013 criteria. Eur J Haematol. 95(6):558-65 - https://onlinelibrary.wiley.com/doi/10.1111/ejh.12536